According to a recent study conducted by researchers at the University of California, Davis, white Americans still make up the overwhelming majority of clinical trials. Non-white people represent fewer than five percent of overall participants, and fewer than two percent of clinical cancer research studies focus specifically on minority groups.
Why is that a problem? Well, because research into cancer among minority groups is stalling at the same time as non-white Americans are bearing more of the country’s cancer burden. For instance, black Americans have the highest rates of cancer — and the shortest rates of survival — of any other racial group in the nation. The gap can be stark. Black women are 40 percent more likely to die of breast cancer than white women. But African Americans represent just 1.3 percent of the participants in cancer clinical trials.
SOURCE: Think Progress